Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD

Fannin Partners has been awarded a $300,000 Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance a first-in-class, non-VEGF–targeted therapeutic for wet age-related macular degeneration (wet AMD), targeting a disease-selective angiogenic...